Research progress in pharmacogenomics of oral antidiabetic drug in type 2 diabetes mellitus
10.3969/j.issn.1006-6187.2017.08.016
- VernacularTitle:2型糖尿病口服降糖药药物基因组学研究进展
- Author:
Yuhua XING
;
Zhiyong PEI
;
Yubao CHEN
- Keywords:
Diabetes mellitus,type 2;
Pharmacogenomics;
Gene polymorphism;
Antidiabetic drugs;
Precision medicine
- From:
Chinese Journal of Diabetes
2017;25(8):748-755
- CountryChina
- Language:Chinese
-
Abstract:
Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disorder,it results from an interaction of environmental as well as genetic factors.There were several kinds of oral antidiabetic drugs (OADs),including biguanides,sulfonylureas,thiazolidinediones,and meglitinides,etc.Several genes have been identified to be associated with disease development and therapeutic outcomes.Inter-individual variations in the human genome affect both,risk of T2DM development and personalized response to identical drug therapies.Pharmacogenomics approaches focus on single nucleotide polymorphisms and their influence on individual drug response,efficacy and toxicity.Therefore,pharmacogenomics in T2DM is of great importance towards precision medicine which will greatly improve the efficacy of diabetes treatment.In this paper,antidiabetic drugs and related gene polymorphism researches are reviewed.
